Gamma System Late Thrombosis Concern Mitigated By Outside Data - Cordis
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson Cordis is hoping for a chance to make its case before FDA's Circulatory System Devices Panel that FDA should consider data neither generated by the company nor included in the premarket approval application for its Gamma brachytherapy system for treatment of coronary artery restenosis.
You may also be interested in...
Implant Sciences System Could Address Gamma Radiation Safety Concerns
Implant Sciences feels its "soft" gamma ray-emitting system for the prevention of restenosis following coronary angioplasty is capable of overcoming hospital personnel safety concerns associated with similar brachytherapy systems.
Implant Sciences System Could Address Gamma Radiation Safety Concerns
Implant Sciences feels its "soft" gamma ray-emitting system for the prevention of restenosis following coronary angioplasty is capable of overcoming hospital personnel safety concerns associated with similar brachytherapy systems.
Novsoste BetaCath Shows Zero Rate Of Late-Stent Thrombosis START Trial
Novoste Corp. appears poised for a smooth path to FDA approval for the BetaCath beta radiation system, given the 0% incidence of late-stent thrombosis in treating patients for in-stent restenosis.